Sunshine Biopharma (SBFM) Non Operating Income (2012 - 2026)
Sunshine Biopharma's (SBFM) quarterly Non Operating Income came in at $48810.0 in Q2 2026, down 34.62% on a YoY basis from $74655.0 in Q2 2025, and down 67.83% quarter-over-quarter from $151728.0 in Q1 2026.
Powered by 
Analysis
Sunshine Biopharma (SBFM) Non Operating Income (2012 - 2026) Analysis & Trends
Sunshine Biopharma (SBFM) has reported Non Operating Income for 14 consecutive years, with $48810.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Non Operating Income fell 34.62% year-over-year to $48810.0; the trailing twelve-month figure through Jun 2026 stood at $323351.0 (up 1192.73% YoY), and the FY2025 full-year result was $273286.0, down 38.33% from the prior year.
- Non Operating Income fell to $48810.0 in Q2 2026 per SBFM's latest filing, from $151728.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $430285.0 in Q2 2024 and bottomed at -$249227.0 in Q4 2024.
- Historically, Non Operating Income has averaged $114227.2 across 5 years, with a median of $106454.0 in 2024.
- The sharpest annual moves came in 2023 and 2024: Non Operating Income jumped 1442.82% in 2023, then slumped 258.28% in 2024.
- Over 5 years, Non Operating Income stood at $84599.0 in 2022, then jumped by 86.13% to $157464.0 in 2023, then plunged by 258.28% to -$249227.0 in 2024, then surged by 123.05% to $57458.0 in 2025, then slipped by 15.05% to $48810.0 in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered $48810.0, $151728.0, and $57458.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.61 Bn | 38.95 Bn | 2.15 Bn | -224.00 Mn |
| 2 | Viatris | 19.18 Bn | 18.30 Bn | 1.46 Bn | - |
| 3 | Dr Reddys Laboratories | 9.85 Bn | 9.68 Bn | 396.53 Mn | - |
| 4 | Amneal Pharmaceuticals | 5.48 Bn | 5.35 Bn | 334.51 Mn | -58.78 Mn |
| 5 | Bausch Health Companies | 2.36 Bn | 518.87 Mn | 2.10 Bn | - |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | - |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | - |
| 8 | Amphastar Pharmaceuticals | 994.21 Mn | 704.09 Mn | 93.47 Mn | -1.19 Mn |
| 9 | Fennec Pharmaceuticals | 405.56 Mn | 364.31 Mn | 17.15 Mn | 278,000.00 |
| 10 | Sunshine Biopharma | 1.56 Mn | -12.19 Mn | 2.43 Mn | 48,810.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 48,810.00 |
| Mar 31, 2026 | 151,728.00 |
| Dec 31, 2025 | 57,458.00 |
| Sep 30, 2025 | 65,355.00 |
| Jun 30, 2025 | 74,655.00 |
| Mar 31, 2025 | 75,818.00 |
| Dec 31, 2024 | -249,227.00 |
| Sep 30, 2024 | 123,767.00 |
| Jun 30, 2024 | 430,285.00 |
| Mar 31, 2024 | 89,141.00 |
| Dec 31, 2023 | 157,464.00 |
| Sep 30, 2023 | 168,944.00 |
| Jun 30, 2023 | 199,457.00 |
| Mar 31, 2023 | 172,821.00 |
| Dec 31, 2022 | 84,599.00 |
| Sep 30, 2022 | 260,961.00 |
| Jun 30, 2022 | 156,924.00 |
| Mar 31, 2022 | -12,870.00 |
| Dec 31, 2021 | 946,747.00 |
| Sep 30, 2021 | -3.54 Mn |